BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
See today's BioWorld Asia
Home
» India's first compulsory license stands; Bayer loses Nexavar appeal
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
India's first compulsory license stands; Bayer loses Nexavar appeal
Dec. 24, 2014
By
T.V. Padma
No Comments
NEW DELHI – India's Supreme Court has dismissed German multinational Bayer AG's appeal against attempts to make and sell cheaper generic versions of its cancer drug, Nexavar (sorafenib tosylate), used to treat liver and rectal cancers.
BioWorld Asia